Current issues of diagnosis and psychopharmacotherapy of post-traumatic stress disorder
|
Full Text:
Subscribers Only
|
Suggested citation:
Akhapkin RV, Vazagaeva TI. [Current issues of diagnosis and psychopharmacotherapy of post-traumatic stress disorder]. Rossiiskii psikhiatricheskii zhurnal [Russian Journal of Psychiatry]. 2025;(1):13-24. Russian
In this scientific review of the narrative type, in order to identify problematic issues and current trends in the diagnosis and psychopharmacotherapy of post-traumatic stress disorder (PTSD), an analysis of scientific publications by Russian and foreign authors in the bibliographic databases PubMed, Google Academy, Science Direct, ResearchGate, Cochrane Library, RSCI and CyberLeninka was carried out. The review discusses the difficulties of diagnosing PTSD related to the variety of its clinical manifestations, traumatic factors and course variants, and the high frequency of concomitant mental and somatic disorders. Treatment of PTSD also involves a number of difficulties due to the lack of proven methods of effective drug treatment. Urgent tasks for future research are the search for new medication methods, the development of differentiated approaches to therapy and predictors of its effectiveness in order to personalize the treatment of patients with PTSD.
Keywords post-traumatic stress disorder; diagnostic criteria; comorbidity; psychopharmacotherapy; antidepressants; antipsychotics; anticonvulsants; anxiolytics
1. Sabé M, Chen C, El-Hage W, et al. Half a Century of Research on Posttraumatic Stress Disorder: A Scientometric Analysis. Curr Neuropharmacol. 2024;22(4):736–48. DOI: 10.2174/1570159X22666230927143106 2. Herrera-Escobar JP, Seshadri AJ, Stanek E, et al. Mental Health Burden After Injury: It's About More than Just Posttraumatic Stress Disorder. Ann Surg. 2021;274(6):e1162–9. DOI: 10.1097/SLA.0000000000003780 3. Bryant RA. Post-traumatic stress disorder: a state-of-the-art review of evidence and challenges. World Psychiatry. 2019;18(3):259–69. DOI: 10.1002/wps.20656 4. Abramova OV, Zorkina YaA, Ushakova VM, et al. [The mental health consequences of prenatal stress: current understanding of mechanisms]. Rossiiskii psikhiatricheskii zhurnal [Russian Journal of Psychiatry]. 2024;(6):92–106. (In Russ.) 5. Bremner JD, Wittbrodt MT. Stress, the brain, and trauma spectrum disorders. Int Rev Neurobiol. 2020;152:1–22. DOI: 10.1016/bs.irn.2020.01.004 6. Ressler KJ, Berretta S, Bolshakov VY, et al. Post-traumatic stress disorder: clinical and translational neuroscience from cells to circuits. Nat Rev Neurol. 2022;18(5):273–88. DOI: 10.1038/s41582-022-00635-8 7. Psikhicheskie rasstroistva i rasstroistva povedeniya (F00–F99): Klass V MKB-10, adaptirovannyi dlya ispol'zovaniya v Rossiiskoi Federatsii. VB Golland, TB Dmitrieva, BA Kazakovtsev, editors. Moscow: Ministry of Health of the Russian Federation; 1998. p. 215–6. (In Russ.) 8. Utzon-Frank N, Breinegaard N, Bertelsen M, et al. Occurrence of delayed-onset post-traumatic stress disorder: a systematic review and meta-analysis of prospective studies. Scand J Work Environ Health. 2014;40(3):215–29. DOI: 10.5271/sjweh.3420 9. Andrews B, Brewin CR, Philpott R, Stewart L. Delayed-onset posttraumatic stress disorder: a systematic review of the evidence. Am J Psychiatry. 2007;164(9):1319–26. DOI: 10.1176/appi.ajp.2007.06091491 10. Horesh D, Solomon Z, Zerach G, Ein-Dor T. Delayed-onset PTSD among war veterans: the role of life events throughout the life cycle. Soc Psychiatry Psychiatr Epidemiol. 2011;46(9):863–70. DOI: 10.1007/s00127-010-0255-6 11. Bonde JPE, Jensen JH, Smid GE, et al. Time course of symptoms in posttraumatic stress disorder with delayed expression: A systematic review. Acta Psychiatr Scand. 2022;145(2):116–31. DOI: 10.1111/acps.13372 12. Smid GE, van der Velden PG, Lensvelt-Mulders GJ, et al. Stress sensitization following a disaster: a prospective study. Psychol Med. 2012;42(8):1675–86. DOI: 10.1017/S0033291711002765 13. Karavaeva TA, Vasileva AV, Idrisov KA, et al. Posttravaticheskoe stressovoe rasstroystvo. Klinicheskie rekomendatsii. 2023. URL: https://cr.minzdrav.gov.ru/schema/753_1 (accessed on: 17.11.2024). (In Russ.) 14. ICD-11. 6B40. Post-traumatic stress disorder. ICD-WHO-INT. URL: https://icd.who.int/browse/2024-01/mms/en#2070699808 (accessed on: 17.11.2024). 15. Parker AM, Sricharoenchai T, Raparla S, et al. Posttraumatic stress disorder in critical illness survivors: a metaanalysis. Crit Care Med. 2015;43(5):1121–9. DOI: 10.1097/CCM.0000000000000882 16. Lunkenheimer F, Garatva P, Steubl L, Baumeister H. Prevalence and incidence of post-traumatic stress disorder and symptoms in people with chronic somatic diseases: A systematic review and meta-analysis. Front Psychiatry. 2023;14:1107–44. DOI: 10.3389/fpsyt.2023.1107144 17. Yunitri N, Chu H, Kang XL, et al. Global prevalence and associated risk factors of posttraumatic stress disorder during COVID-19 pandemic: A meta-analysis. Int J Nurs Stud. 2022;126:104–36. DOI: 10.1016/j.ijnurstu.2021.104136 18. Vasileva AV. [Pandemic COVID-19 and mental disorders international experience and therapeutic approaches]. Zh Nevrol Psikhiatr Im SS Korsakova. 2020;120(9):121–9. (In Russ.) DOI: 10.17116/jnevro2020120091121 19. ICD-11. 6B41. Complex post-traumatic stress disorder. ICD-WHO-INT. URL: https://icd.who.int/browse/2024-01/mms/en#585833559 (accessed on: 17.11.2024). 20. Letica-Crepulja M, Stevanović A, Protuđer M, et al. Complex PTSD among treatment-seeking veterans with PTSD. Eur J Psychotraumatol. 2020;11(1):1716593. DOI: 10.1080/20008198.2020.1716593 21. Grinsill R, Kolandaisamy M, Kerr K, et al. Prevalence of Complex Post-Traumatic Stress Disorder in Serving Military and Veteran Populations: A Systematic Review. Trauma Violence Abuse. 2024;25(4):3377–87. DOI: 10.1177/15248380241246996 22. Qassem T, Aly-ElGabry D, Alzarouni A, et al. Psychiatric Co-Morbidities in Post-Traumatic Stress Disorder: Detailed Findings from the Adult Psychiatric Morbidity Survey in the English Population. Psychiatr Q. 2021;92(1):321–30. DOI: 10.1007/s11126-020-09797-4 23. Husky MM, Mazure CM, Kovess-Masfety V. Gender differences in psychiatric and medical comorbidity with post-traumatic stress disorder. Compr Psychiatry. 2018;84:75–81. DOI: 10.1016/j.comppsych.2018.04.007 24. Nickerson A, Barnes JB, Creamer M, et al. The temporal relationship between posttraumatic stress disorder and problem alcohol use following traumatic injury. J Abnorm Psychol. 2014;123(4):821–34. DOI: 10.1037/a0037920 25. Hicks EM, Niarchou M, Goleva S, et al. Comorbidity Profiles of Posttraumatic Stress Disorder Across the Medical Phenome. Biol Psychiatry Glob Open Sci. 2024;4(5):100337. DOI: 10.1016/j.bpsgos.2024.100337 26. Veltishchev DYu. [Interrelation of posttraumatic stress disorder and cardiovascular disease]. Sotsial'naya i klinicheskaya psikhiatriya [Social and Clinical Psychiatry]. 2023;33(4):76–80. (In Russ.) DOI: 10.34757/0869-4893.2023.33.4.009 27. Brady KT, McCauley JL, Back SE. The Comorbidity of Post-traumatic Stress Disorder (PTSD) and Substance Use Disorders. In: Textbook of Addiction Treatment. N el-Guebaly, G Carrà, M Galanter, AM Baldacchino, editors. Springer, Cham; 2021. Chapter 93. р. 1327–39. DOI: 10.1007/978-3-030-36391-8_93 28. Hoppen TH, Priebe S, Vetter I, Morina N. Global burden of post-traumatic stress disorder and major depression in countries affected by war between 1989 and 2019: a systematic review and meta-analysis. BMJ Glob Health. 2021;6(7):e006303. DOI: 10.1136/bmjgh-2021-006303 29. Tarabrina NV. Praktikum po psikhologii posttravmaticheskogo stressa. Saint Petersburg: Piter; 2001. 272 р. (In Russ.) 30. Selaman ZM, Chartrand HK, Bolton JM, Sareen J. Which symptoms of post-traumatic stress disorder are associated with suicide attempts? J Anxiety Disord. 2014;28(2):246–51. DOI: 10.1016/j.janxdis.2013.12.005 31. Weber FC, Norra C, Wetter TC. Sleep Disturbances and Suicidality in Posttraumatic Stress Disorder: An Overview of the Literature. Front Psychiatry. 2020;10(11):167. DOI: 10.3389/fpsyt.2020.00167 32. McLaughlin KA, Koenen KC, Friedman MJ, et al. Subthreshold posttraumatic stress disorder in the world health organization world mental health surveys. Biol Psychiatry. 2015;77(4):375–84. DOI: 10.1016/j.biopsych.2014.03.028 33. Panagioti M, Gooding PA, Tarrier N. A meta-analysis of the association between posttraumatic stress disorder and suicidality: the role of comorbid depression. Compr Psychiatry. 2012;53(7):915–30. DOI: 10.1016/j.comppsych.2012.02.009 34. Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168(12):1266–77. DOI: 10.1176/appi.ajp.2011.10111704 35. Bobrov AE. [Some unresolved issues of psychotherapy and organization of stress disorders care]. Sotsial'naya i klinicheskaya psikhiatriya [Social and Clinical Psychiatry]. 2023;33(4):6775. (In Russ.) DOI: 10.34757/0869-4893.2023.33.4.008 36. Mosolov SN. [Therapy and prevention of post-traumatic stress disorder in emergency situations (algorithm of biological therapy)]. Sovremennaja terapija psihicheskih rasstrojstv [Current therapy of mental disorders]. 2022;(3):32–44. (In Russ.) DOI 10.21265/PSYPH.2022.92.41.004 37. Bandelow B, Allgulander C, Baldwin DS, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders – Version 3. Part II: OCD and PTSD. World J Biol Psychiatry. 2023;24(2):118–34. DOI: 10.1080/15622975.2022.2086296 38. Ressler KJ. Alpha-Adrenergic Receptors in PTSD – Failure or Time for Precision Medicine? N Engl J Med. 2018;378(6):575–6. DOI: 10.1056/NEJMe1716724 39. Davidson J, Pearlstein T, Londborg P, et al. Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo-controlled study. Am J Psychiatry. 2001;158(12):1974–81. DOI: 10.1176/appi.ajp.158.12.1974 40. Rapaport MH, Endicott J, Clary CM. Posttraumatic stress disorder and quality of life: results across 64 weeks of sertraline treatment. J Clin Psychiatry. 2002;63(1):59–65. DOI: 10.4088/jcp.v63n0112 41. Marshall RD, Lewis-Fernandez R, Blanco C, et al. A controlled trial of paroxetine for chronic PTSD, dissociation, and interpersonal problems in mostly minority adults. Depress Anxiety. 2007;24(2):77–84. DOI: 10.1002/da.20176 42. Tucker P, Zaninelli R, Yehuda R, et al. Paroxetine in the treatment of chronic posttraumatic stress disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry. 2001;62(11):860–8. DOI: 10.4088/jcp.v62n1105 43. Davidson J, Rothbaum BO, Tucker P, et al. Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study. J Clin Psychopharmacol. 2006;26(3):259–67. DOI: 10.1097/01.jcp.0000222514.71390.c1 44. Davidson J, Baldwin D, Stein DJ, et al. Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial. Arch Gen Psychiatry. 2006;63(10):1158–65. DOI: 10.1001/archpsyc.63.10.1158 45. Martenyi F, Brown EB, Zhang H, et al. Fluoxetine versus placebo in posttraumatic stress disorder. J Clin Psychiatry. 2002;63(3):199–206. DOI: 10.4088/jcp.v63n0305 46. Williams T, Phillips NJ, Stein DJ, Ipser JC. Pharmacotherapy for post-traumatic stress disorder (PTSD). Cochrane Database Syst Rev. 2022;3(3):CD002795. DOI: 10.1002/14651858.CD002795.pub3 47. Villarreal G, Cañive JM, Calais LA, et al. Duloxetine in military posttraumatic stress disorder. Psychopharmacol Bull. 2010;43(3):26–34. PMID: 21150844 48. Davis LL, Pilkinton P, Lin C, et al. Efficacy of Vortioxetine Monotherapy for Posttraumatic Stress Disorder: A Randomized, Placebo-Controlled Trial. J Clin Psychopharmacol. 2021;41(2):172–9. DOI: 10.1097/JCP.0000000000001363 49. Escalona R, Canive JM, Calais LA, Davidson JR. Fluvoxamine treatment in veterans with combat-related post-traumatic stress disorder. Depress Anxiety. 2002;15(1):29–33. DOI: 10.1002/da.1082 50. Qi W, Gevonden M, Shalev A. Efficacy and Tolerability of High-Dose Escitalopram in Posttraumatic Stress Disorder. J Clin Psychopharmacol. 2017;37(1):89–93. DOI: 10.1097/JCP.0000000000000626 51. Davidson JR, Weisler RH, Butterfield MI, et al. Mirtazapine vs. placebo in posttraumatic stress disorder: a pilot trial. Biol Psychiatry. 2003;53(2):188–91. DOI: 10.1016/s0006-3223(02)01411-7 52. Kim W, Pae CU, Chae JH, et al. The effectiveness of mirtazapine in the treatment of post-traumatic stress disorder: a 24-week continuation therapy. Psychiatry Clin Neurosci. 2005;59(6):743–7. DOI: 10.1111/j.1440-1819.2005.01447.x 53. Davis LL, Pilkinton P, Lin C, et al. A Randomized, Placebo-Controlled Trial of Mirtazapine for the Treatment of Posttraumatic Stress Disorder in Veterans. J Clin Psychiatry. 2020;81(6):20m13267. DOI: 10.4088/JCP.20m13267 54. Lappas AS, Glarou E, Polyzopoulou ZA, et al. Pharmacotherapy for sleep disturbances in post-traumatic stress disorder (PTSD): A network meta-analysis. Sleep Med. 2024;119:467–79. DOI: 10.1016/j.sleep.2024.05.032 55. Warner MD, Dorn MR, Peabody CA. Survey on the usefulness of trazodone in patients with PTSD with insomnia or nightmares. Pharmacopsychiatry. 2001;34(4):128–31. DOI: 10.1055/s-2001-15871 56. Davidson J, Kudler H, Smith R, et al. Treatment of posttraumatic stress disorder with amitriptyline and placebo. Arch Gen Psychiatry. 1990;47(3):259–66. DOI: 10.1001/archpsyc.1990.01810150059010 57. Davidson JR, Kudler HS, Saunders WB, et al. Predicting response to amitriptyline in posttraumatic stress disorder. Am J Psychiatry. 1993;150(7):1024–9. DOI: 10.1176/ajp.150.7.1024 58. Frank JB, Kosten TR, Giller EL Jr, Dan E. A randomized clinical trial of phenelzine and imipramine for posttraumatic stress disorder. Am J Psychiatry. 1988;145(10):1289–91. DOI: 10.1176/ajp.145.10.1289 59. Kosten TR, Frank JB, Dan E, et al. Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine. J Nerv Ment Dis. 1991;179(6):366–70. DOI: 10.1097/00005053-199106000-00011 60. Pae CU, Lim HK, Peindl K, et al. The atypical antipsychotics olanzapine and risperidone in the treatment of posttraumatic stress disorder: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials. Int Clin Psychopharmacol. 2008;23(1):1–8. DOI: 10.1097/YIC.0b013e32825ea324 61. David D, De Faria L, Mellman TA. Adjunctive risperidone treatment and sleep symptoms in combat veterans with chronic PTSD. Depress Anxiety. 2006;23(8):489–91. DOI: 10.1002/da.20187 62. Britnell SR, Jackson AD, Brown JN, Capehart BP. Aripiprazole for Post-traumatic Stress Disorder: A Systematic Review. Clin Neuropharmacol. 2017;40(6):273–8. DOI: 10.1097/WNF.0000000000000251 63. Naylor JC, Kilts JD, Bradford DW, et al. A pilot randomized placebo-controlled trial of adjunctive aripiprazole for chronic PTSD in US military Veterans resistant to antidepressant treatment. Int Clin Psychopharmacol. 2015;30(3):167–74. DOI: 10.1097/YIC.0000000000000061 64. El-Solh AA. Management of nightmares in patients with posttraumatic stress disorder: current perspectives. Nat Sci Sleep. 2018;10:409–20. DOI: 10.2147/NSS.S166089 65. Ramaswamy S, Driscoll D, Smith LM, et al. Failed efficacy of ziprasidone in the treatment of post-traumatic stress disorder. Contemp Clin Trials Commun. 2015;2:1–5. DOI: 10.1016/j.conctc.2015.12.003 66. Hamner MB, Hernandez-Tejada MA, Zuschlag ZD, et al. Ziprasidone Augmentation of SSRI Antidepressants in Posttraumatic Stress Disorder: A Randomized, Placebo-Controlled Pilot Study of Augmentation Therapy. J Clin Psychopharmacol. 2019;39(2):153–7. DOI: 10.1097/JCP.0000000000001000 67. Hoskins MD, Bridges J, Sinnerton R, et al. Pharmacological therapy for post-traumatic stress disorder: a systematic review and meta-analysis of monotherapy, augmentation and head-to-head approaches. Eur J Psychotraumatol. 2021;12(1):1802920. DOI: 10.1080/20008198.2020.1802920 68. Villarreal G, Hamner MB, Cañive JM, et al. Efficacy of Quetiapine Monotherapy in Posttraumatic Stress Disorder: A Randomized, Placebo-Controlled Trial. Am J Psychiatry. 2016;173(12):1205–12. DOI: 10.1176/appi.ajp.2016.15070967 69. Crapanzano C, Damiani S, Casolaro I, Amendola C. Quetiapine Treatment for Post-traumatic Stress Disorder: A Systematic Review of the Literature. Clin Psychopharmacol Neurosci. 2023;21(1):49–56. DOI: 10.9758/cpn.2023.21.1.49 70. Berlin HA. Antiepileptic drugs for the treatment of post-traumatic stress disorder. Curr Psychiatr Rep. 2007;9(4):291–300. DOI: 10.1007/s11920-007-0035-5 71. Yeh MS, Mari JJ, Costa MC, et al. A double-blind randomized controlled trial to study the efficacy of topiramate in a civilian sample of PTSD. CNS Neurosci Ther. 2011;17(5):305–10. DOI: 10.1111/j.1755-5949.2010.00188.x 72. Varma A, Moore MB, Miller CWT, et al. Topiramate as monotherapy or adjunctive treatment for posttraumatic stress disorder: a meta-analysis. J Trauma Stress. 2018;31(1):125–33. DOI: 10.1002/jts.22251 73. Lindley SE, Carlson EB, Hill K. A randomized, double-blind, placebo-controlled trial of augmentation topiramate for chronic combat-related posttraumatic stress disorder. J Clin Psychopharmacol. 2007;27(6):677–81. DOI: 10.1097/jcp.0b013e31815a43ee 74. Clark RD, Cañive JM, Calais LA, et al. Divalproex in posttraumatic stress disorder: an open label clinical trial. J Trauma Stress. 1999;12(2):395–401. DOI: 10.1023/A:1024797014210 75. Hamner MB, Faldowski RA, Robert S, et al. A preliminary controlled trial of divalproex in posttraumatic stress disorder. Ann Clin Psychiatr. 2009;21(2):89–94. PMID: 19439158 76. Davis LL, Davidson JR, Ward LC, et al. Divalproex in the treatment of posttraumatic stress disorder: a randomized, double-blind, placebo-controlled trial in a veteran population. J Clin Psychopharmacol. 2008;28(1):84–8. DOI: 10.1097/JCP.0b013e318160f83b 77. De Moraes Costa G, Zanatta FB, Ziegelmannet PK, et al. Pharmacological treatments for adults with post-traumatic stress disorder: a network meta-analysis of comparative efficacy and acceptability. J Psychiatr Res. 2020;130:412–20. DOI: 10.1016/j.jpsychires.2020.07.046 78. Hertzberg MA, Butterfield MI, Feldman ME, et al. A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder. Biol Psychiatry. 1999;45(9):1226–9. DOI: 10.1016/s0006-3223(99)00011-6 79. Thompson SI, El-Saden SM. Lamotrigine for Treating Anger in Veterans With Posttraumatic Stress Disorder. Clin Neuropharmacol. 2021;44(5):184–5. DOI: 10.1097/WNF.0000000000000477 80. Gasparyan A, Navarroa D, Navarretea F, Manzanares J. Pharmacological strategies for post-traumatic stress disorder (PTSD): From animal to clinical studies. Neuropharmacology. 2022;218:n109211. DOI: 10.1016/j.neuropharm.2022.109211 81. Davidson JR, Brady K, Mellman TA, et al. The efficacy and tolerability of tiagabine in adult patients with post-traumatic stress disorder. J Clin Psychopharmacol. 2007;27(1):85–8. DOI: 10.1097/JCP.0b013e31802e5115 82. Kinrys G, Wygant L, Pardo TB, et al. Levetiracetam for treatment-refractory posttraumatic stress disorder. J Clin Psychiatr. 2006;67(2):211–4. DOI: 10.4088/jcp.v67n0206 83. Baniasadi M, Hosseini G, Fayyazi B, et al. Effect of pregabalin augmentation in treatment of patients with combat-related chronic posttraumatic stress disorder: a randomized controlled trial. J Psychiatr Pract. 2014;20(6):419–27. DOI: 10.1097/01.pra.0000456590.12998.41 84. De Crescenzo F, D'Alò GL, Ostinelli EG, et al. Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis. Lancet. 2022;400(10347):170–84. DOI: 10.1016/S0140-6736(22)00878-9 85. Lappas AS, Glarou E, Polyzopoulou ZA, et al. Pharmacotherapy for sleep disturbances in post-traumatic stress disorder (PTSD): A network meta-analysis. Sleep Med. 2024;119:467–79. DOI: 10.1016/j.sleep.2024.05.032 86. Guina J, Rossetter SR, DeRhodes BJ, et al. Benzodiazepines for PTSD: A Systematic Review and Meta-Analysis. J Psychiatr Pract. 2015;21(4):281–303. DOI: 10.1097/PRA.0000000000000091 87. Huang CY, Zhao YF, Zhang ZX, et al. Psychotherapeutic and pharmacological agents for post-traumatic stress disorder with sleep disorder: network meta-analysis. Ann Med. 2024;56(1):2381696. DOI: 10.1080/07853890.2024.2381696 88. Duffy JD, Malloy PF. Efficacy of buspirone in the treatment of posttraumatic stress disorder: an open trial. Ann Clin Psychiatry. 1994;6(1):33–7. DOI: 10.3109/10401239409148837 89. Hamner M, Ulmer H, Horne D. Buspirone potentiation of antidepressants in the treatment of PTSD. Depress Anxiety. 1997;5(3):137–9. DOI: 10.1002/(SICI)1520-6394(1997)5:3<137::AID-DA6>3.0.CO;2-B 90. Vasileva AV. [Post-traumatic stress disorder – from traumatic neurosis to ICD-11: features of diagnosis and selection of therapy]. Meditsinskiy sovet [Medical Council]. 2023;(3):94–108. (In Russ.) DOI: 10.21518/ms2023-083 91. Malikowska-Racia N, Salat K. Recent advances in the neurobiology of posttraumatic stress disorder: A review of possible mechanisms underlying an effective pharmacotherapy. Pharmacol Res. 2019;142:30–49. DOI: 10.1016/j.phrs.2019.02.001 92. Stein DJ. Etifoxine versus alprazolam for the treatment of adjustment disorder with anxiety: a randomized controlled trial. Adv Ther. 2015;32(1):57–68. DOI: 10.1007/s12325-015-0176-6 93. Zhang Y, Ren R, Sanford LD, et al. The effects of prazosin on sleep disturbances in post-traumatic stress disorder: a systematic review and meta-analysis. Sleep Med. 2020;67:225–31. DOI: 10.1016/j.sleep.2019.06.010 94. Reist C, Streja E, Tang CC, et al. Prazosin for treatment of post-traumatic stress disorder: A systematic review and meta-analysis. CNS Spectr. 2021;26(4):338–44. DOI: 10.1017/S1092852920001121
Article Metrics
Metrics powered by PLOS ALM